Boston Scientific Earnings Preview: Analysts Expect Rising Revenue, Falling EPS Over Previous Quarter

Boston Scientific BSX announces its next round of earnings this Thursday, July 28, 2011. Get prepared with Benzinga's ultimate preview for Boston Scientific's second quarter earnings.

Earnings and Revenue:

Analysts are predicting an EPS reading of 8 cents per share and revenues of $1.94 billion. Wall Street will be looking to see how this quarter's numbers compare to the year-ago quarter's positive EPS of 6 cents per share on revenues of $1.93 billion. We'll have to wait for Thursday to see if Boston Scientific has accomplished the estimated 33.3% rise in EPS and 0.5% increase in revenues on a year-over-year basis.

Here's how the company's reported EPS has stacked up against analyst estimates in the past:

Stock Performance:

At last check, shares of Boston Scientific were trading at $7.21. Shares are down 4.8% year to date. For a full 12 months, the return has risen by 17.6%. Given that these returns are generally positive, long-term shareholders are probably satisfied going into this earnings release.

• Long-term shareholders are already enjoying 12-month gains prior to the announcement

Average Stock Rating:

The average rating by analysts for Boston Scientific is a Hold. This rating has strengthened slightly over the past ninety days.

Competitors:

Want to check out the performance of Boston Scientific closest competitors? Take a look at some of the company's peers in the healthcare sector.

• Abbott Laboratories ABT: Hold with a $1.12 recent quarter EPS
• C.R. Bard BCR: Hold with a $1.57 recent quarter EPS
• Johnson & Johnson JNJ: Moderate Buy with a $1.28 recent quarter EPS
• Medtronic MDT: Hold with a $0.90 recent quarter EPS

Boston Scientific is in the medical products industry, which has experienced price/earnings growth of 1.5%.

Finally, a description of the company's main areas of operation: Boston Scientific offers medical devices used in interventional cardiology, cardiac rhythm management, peripheral interventions, endoscopy, gynecology, electrophysiology, neurovascular intervention and neuromodulation.

Take Action:

That's your advanced look at Boston Scientific's upcoming earnings numbers -- be ready to take quick action if the company's report contains any surprises. Also, check back in with us after the announcement for a full recap and what-to-do-next guide.

• To see up-to-date news on Boston Scientific, click here
• To see other trading ideas, click here
• To see other company earnings recaps, click here